Key Points
- Director Peter Feinberg purchased 20,000 shares at an average price of $4.35 on Jan 12 for a total of $87,000, boosting his stake to 135,441 shares (a 17.32% increase).
- Large institutions have been building positions—Sanofi, Vanguard, Citadel and others added stakes—and institutional investors now own about 67.65% of the company.
- Shares opened around $4.43 (up ~7%); Immuneering has a market cap of $286M and a consensus analyst rating of "Moderate Buy" with an average target price of $16.50.
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Peter Feinberg bought 20,000 shares of the business's stock in a transaction on Monday, January 12th. The stock was purchased at an average cost of $4.35 per share, for a total transaction of $87,000.00. Following the transaction, the director owned 135,441 shares of the company's stock, valued at $589,168.35. This trade represents a 17.32% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Immuneering Stock Up 7.0%
IMRX opened at $4.43 on Thursday. Immuneering Corporation has a 52 week low of $1.10 and a 52 week high of $10.08. The business has a fifty day simple moving average of $6.45 and a 200-day simple moving average of $5.78. The firm has a market cap of $286.05 million, a P/E ratio of -2.49 and a beta of 0.48.
Immuneering (NASDAQ:IMRX - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). Sell-side analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current year.
Institutional Investors Weigh In On Immuneering
Hedge funds and other institutional investors have recently modified their holdings of the company. Sanofi purchased a new stake in shares of Immuneering during the 3rd quarter worth $18,960,000. Vanguard Group Inc. raised its stake in Immuneering by 128.5% in the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company's stock valued at $16,907,000 after buying an additional 1,358,322 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Immuneering during the 3rd quarter worth about $6,602,000. Blue Owl Capital Holdings LP acquired a new position in shares of Immuneering during the 3rd quarter worth about $3,850,000. Finally, Monashee Investment Management LLC purchased a new position in shares of Immuneering in the 3rd quarter valued at about $2,100,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Leerink Partners began coverage on shares of Immuneering in a report on Friday, October 31st. They issued an "outperform" rating and a $15.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Immuneering in a research note on Monday, December 29th. Chardan Capital reiterated a "buy" rating and issued a $20.00 price objective on shares of Immuneering in a research note on Thursday, November 13th. Wall Street Zen lowered Immuneering from a "hold" rating to a "sell" rating in a report on Saturday, December 20th. Finally, Leerink Partnrs raised Immuneering to a "strong-buy" rating in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $16.50.
View Our Latest Analysis on IMRX
About Immuneering
(
Get Free Report)
Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.
The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
